Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
Drug Details
- Generic Name
- Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
- Brand Names
- SYMFI, Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
- Application Number
- NDA022142
- Sponsor
- Viatris Specialty LLC
- NDC Codes
- 3
- Dosage Forms
- TABLET, FILM COATED
- Routes
- ORAL
- Active Ingredients
- EFAVIRENZ, LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE
Indications and Usage
1 INDICATIONS AND USAGE SYMFI ® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. SYMFI is a three-drug combination of efavirenz (EFV), a non-nucleoside reverse transcriptase inhibitor, and lamivudine (3TC) and tenofovir disoproxil fumarate (TDF), both nucleo(t)side reverse transcriptase inhibitors and is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. ( 1 )